Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lesogaberan add-on to PPI in GERD
NCT01005251Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lesogaberan in gastroesophageal reflux disease (GERD) (5 arms), sponsored by AstraZeneca. Primary endpoint: Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week at 4 weeks. Started Oct 2009; status: completed.
02
Drugs
lesogaberan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01005251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01005251.